Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | PLA2G4B | P0C869 | 5/20 | 0.38 |
| ▸ | PPARD | Q03181 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8484161 | 0.86 | ALDH1A1 (0.47) | PLA2G4BALDH1A1TDP1L3MBTL1PLA2G4A | |
| SCHEMBL832556 | 0.82 | CYP3A4 (0.46) | PPARDTDP1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL830138 | 0.82 | L3MBTL1 (0.41) | PPARGPPARATDP1L3MBTL1CYP1A2 | |
| SCHEMBL15910098 | 0.78 | CYP3A4 (0.43) | PPARDALDH1A1TDP1CYP1A2CYP3A4 | |
| SCHEMBL414168 | 0.77 | CYP1A2 (0.50) | CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL9964595 | 0.75 | L3MBTL1 (0.37) | TDP1L3MBTL1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL15371969 | 0.75 | CYP3A4 (0.43) | PPARGPPARDPPARATDP1CYP1A2 | |
| SCHEMBL863376 | 0.75 | L3MBTL1 (0.47) | PPARDPPARAALDH1A1L3MBTL1 | |
| SCHEMBL9964592 | 0.74 | CYP3A4 (0.39) | PPARDPPARATDP1L3MBTL1CYP1A2 | |
| SCHEMBL3707532 | 0.73 | NR5A1 (0.54) | PLA2G4BPLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025024656-A1 | POLYESTER URETHANE BIORESORBABLE ELASTOMERS WITH MICROSTRUCTURES FOR TUNABLE DRUG RELEASE AND TUNABLE DEGRADATION | SOLESIS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| US-20250034331-A1 | POLYESTER URETHANE BIORESORBABLE ELASTOMERS WITH MICROSTRUCTURES FOR TUNABLE DRUG RELEASE AND TUNABLE DEGRADATION | SOLESIS LLC | 2025-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034331-A1 | POLYESTER URETHANE BIORESORBABLE ELASTOMERS WITH MICROSTRUCTURES FOR TUNABLE DRUG RELEASE AND TUNABLE DEGRADATION | PUF60, UTS2R, UROD | PPARG 3782/4885PTGES 344/4885ALOX5 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.